WithdrawnPHASE1, PHASE2NCT04482712

Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS

Studying Acute lung injury

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
The University of Texas Health Science Center at San Antonio
Principal Investigator
Dean L Kellogg, MD, PhD
University of Texas Health at San Antonio
Intervention
Rapamycin(drug)
Eligibility
60 years · All sexes
Timeline
20212023

Study locations (2)

Collaborators

The Claude D. Pepper Older Americans Independence Centers

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04482712 on ClinicalTrials.gov

Other trials for Acute lung injury

Additional recruiting or active studies for the same condition.

See all trials for Acute lung injury

← Back to all trials